These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10933870)

  • 21. A novel single nucleotide polymorphism altering stability and activity of CYP2a6.
    Ariyoshi N; Sawamura Y; Kamataki T
    Biochem Biophys Res Commun; 2001 Mar; 281(3):810-4. PubMed ID: 11237731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiency.
    Broly F; Marez D; Lo Guidice JM; Sabbagh N; Legrand M; Boone P; Meyer UA
    Hum Genet; 1995 Nov; 96(5):601-3. PubMed ID: 8530011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel mutations in the cytochrome P450 2C19 gene: a pitfall of the PCR-RFLP method for identifying a common mutation.
    Ohkubo Y; Ueta A; Ando N; Ito T; Yamaguchi S; Mizuno K; Sumi S; Maeda T; Yamazaki D; Kurono Y; Fujimoto S; Togari H
    J Hum Genet; 2006; 51(2):118-123. PubMed ID: 16307177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phenytoin intoxication induced by fluvoxamine.
    Mamiya K; Kojima K; Yukawa E; Higuchi S; Ieiri I; Ninomiya H; Tashiro N
    Ther Drug Monit; 2001 Feb; 23(1):75-7. PubMed ID: 11206048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Misclassification of allele CYP2C19*10 as CY2C19*2 by a commonly used PCR-RFLP procedure.
    Rasmussen H; Werge T
    Genet Test; 2008 Mar; 12(1):57-8. PubMed ID: 18373404
    [No Abstract]   [Full Text] [Related]  

  • 26. Two single-tube tetra-primer assays to detect the CYP2C19*2 and *3 alleles of S-mephenytoin hydroxylase.
    Hersberger M; Marti-Jaun J; Rentsch K; Hänseler E
    Clin Chem; 2001 Apr; 47(4):772-4. PubMed ID: 11274039
    [No Abstract]   [Full Text] [Related]  

  • 27. Identification of major CYP2C9 and CYP2C19 polymorphisms by fluorescence resonance energy transfer analysis.
    Borlak J; Thum T
    Clin Chem; 2002 Sep; 48(9):1592-4. PubMed ID: 12194942
    [No Abstract]   [Full Text] [Related]  

  • 28. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
    Odani A; Hashimoto Y; Otsuki Y; Uwai Y; Hattori H; Furusho K; Inui K
    Clin Pharmacol Ther; 1997 Sep; 62(3):287-92. PubMed ID: 9333104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Genetic polymorphism of drug metabolizing enzymes].
    Yokoi T; Kamataki T
    Seikagaku; 1997 Oct; 69(10):1196-9. PubMed ID: 9431010
    [No Abstract]   [Full Text] [Related]  

  • 30. AmpliChip CYP450 test.
    Med Lett Drugs Ther; 2005 Aug 15-29; 47(1215-1216):71-2. PubMed ID: 16103869
    [No Abstract]   [Full Text] [Related]  

  • 31. CYP2C19 genetic mutations in North Indians.
    Lamba JK; Dhiman RK; Kohli KK
    Clin Pharmacol Ther; 2000 Sep; 68(3):328-35. PubMed ID: 11014415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Advances in the study of pharmacogenetics in China in 1996].
    Xie H; Zhou H
    Zhonghua Yi Xue Za Zhi; 1997 Jan; 77(1):77-8. PubMed ID: 9596985
    [No Abstract]   [Full Text] [Related]  

  • 33. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
    Tanigawara Y; Aoyama N; Kita T; Shirakawa K; Komada F; Kasuga M; Okumura K
    Clin Pharmacol Ther; 1999 Nov; 66(5):528-34. PubMed ID: 10579481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetics of CYP2C subfamily in a Japanese population.
    Ieiri I; Higuchi S
    J Toxicol Sci; 1998 Jul; 23 Suppl 2():129-31. PubMed ID: 9760448
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacogenetics of cytochromes P450.
    Hasler JA
    Mol Aspects Med; 1999; 20(1-2):12-24, 25-137. PubMed ID: 10575648
    [No Abstract]   [Full Text] [Related]  

  • 36. High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands.
    Kaneko A; Lum JK; Yaviong L; Takahashi N; Ishizaki T; Bertilsson L; Kobayakawa T; Björkman A
    Pharmacogenetics; 1999 Oct; 9(5):581-90. PubMed ID: 10591538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genotoxicology and risk assessment in the era of the human genome project.
    Vorce RL; Stemmer PM
    J Toxicol Clin Toxicol; 1996; 34(5):521-3. PubMed ID: 8800191
    [No Abstract]   [Full Text] [Related]  

  • 38. The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP.
    Kitagawa K; Kunugita N; Katoh T; Yang M; Kawamoto T
    Biochem Biophys Res Commun; 1999 Aug; 262(1):146-51. PubMed ID: 10448083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The CYP2C19 enzyme polymorphism.
    Wedlund PJ
    Pharmacology; 2000 Sep; 61(3):174-83. PubMed ID: 10971203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic polymorphism of debrisoquine oxidation: restriction fragment analysis and allele-specific amplification of mutant alleles of CYP2D6.
    Heim MH; Meyer UA
    Methods Enzymol; 1991; 206():173-83. PubMed ID: 1686063
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.